The basics:
- Teva will eliminate 61 jobs in NJ by Feb. 1, 2027
- Fairfield closure tied to declining demand and price erosion
- Parsippany, Edison sites will remain open
- Teva targets $700M in savings through 2027
Teva Pharmaceuticals USA said it will move manufacturing out of New Jersey as early as next year under a broader restructuring effort.
Ahead of the change, the generic drugs and specialty medicines maker expects to eliminate 61 positions at its Fairfield site by Feb. 1, 2027, according to a filing with the New Jersey Department of Labor & Workforce Development.
A company spokesperson told NJBIZ the closure of the Gloria Lane facility is tied to an “ongoing review of our global operations network.”
“Despite efforts to increase production, the site remains underutilized and costly to operate, while declining demand and price erosion have further impacted its economic viability,” they said.
“The decision to close the site supports resource optimization and enables Teva to focus investments on areas that best support reliable supply of safe, effective, and high-quality medicines. Teva will maintain a strong presence in the United States, including in New Jersey, across commercial, R&D, manufacturing, and distribution operations,” the media representative went on.
Teva’s tax break
In May 2025, Teva unveiled a transformation strategy targeting about $700 million in net savings through 2027 via organizational modernization, cost cutting and operational efficiencies.
The plan also calls for an 8% reduction in workforce by the end of next year. According to BioSpace, that amounts to some 2,900 employees worldwide.
The Fairfield closure comes roughly eight years after the Israel-based pharmaceutical company relocated its U.S. headquarters from North Wales, Pa., to Parsippany. At the time, Teva already had its manufacturing space in Fairfield and an R&D facility in Elizabeth.
Under former Gov. Phil Murphy, the New Jersey Economic Development Authority approved a tax credit package worth up to nearly $40 million over 10 years to support Teva’s move to the state. The company projected that coming to New Jersey would bring or create 843 jobs while retaining another 232 positions.
Besides Fairfield and Parsippany, Teva maintains a packaging operation in Edison. The company spokesperson confirmed to NJBIZ that its sites in Parsippany and Edison will remain open. Meanwhile, the Elizabeth facility closed a few years ago, they said.
Founded 125 years ago in Jerusalem, Teva develops and manufactures generic drugs, branded medicines, biosimilars and over-the-counter products. As of Dec. 31, 2025, the company had about 33,950 employees, operations in 57 markets and 30 manufacturing sites globally.
Teva recently reported a 1% year-over-year decline in second quarter revenue to $4.14 billion. The drop reflects weaker sales of generic medicines and increased price competition, alongside supply chain challenges.
Teva isn’t the only pharma giant looking to expand its manufacturing presence in other states.
Recently announced projects from NJ pharmas include:
- Bristol Myers Squibb’s $2.3 billion manufacturing campus in Texas
- Bayer’s $2.2 billion manufacturing site in Ohio
- Novartis’ $771 million production hub
- Johnson & Johnson’s $1 billion distribution facility in Florida
With the exception of Bayer, all of those companies have signed deals with the White House pledging to ramp up domestic production in exchange for tariff exemptions.
The post Teva to cut 61 jobs in Fairfield as it moves manufacturing out of NJ appeared first on NJBIZ.

